| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Zylofuramine targets monoamine transporters, including the dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT). By blocking the reuptake of these neurotransmitters, it increases their extracellular concentrations in the synaptic cleft, leading to enhanced neurotransmission and psychostimulant effects.
|
|---|---|
| ln Vitro |
In vitro, Zylofuramine acts as a psychomotor stimulant by blocking the reuptake of dopamine, norepinephrine, and serotonin. Its activity is assessed using neurotransmitter reuptake inhibition assays in cells expressing the respective transporters. The compound's potency and selectivity for each transporter are determined by measuring its ability to inhibit the uptake of radiolabeled neurotransmitters.
|
| ln Vivo |
In vivo, Zylofuramine has stimulant effects on the central nervous system, resulting in increased alertness, energy, and euphoria. It belongs to the class of amphetamine derivatives and has been studied for its psychomotor stimulant properties.
|
| Enzyme Assay |
In vitro neurotransmitter reuptake assays for Zylofuramine are performed using cells expressing human dopamine, norepinephrine, or serotonin transporters. Cells are incubated with the compound and a radiolabeled neurotransmitter (e.g., [³H]-dopamine, [³H]-norepinephrine, or [³H]-serotonin), and the amount of radioactivity taken up into cells is measured. The IC50 for inhibition of reuptake is calculated from concentration-response curves.
|
| Cell Assay |
In vitro cellular assays for Zylofuramine are performed using neuronal cell lines or primary neurons. Cells are treated with the compound, and neurotransmitter levels in the extracellular medium are measured using HPLC or other analytical methods. The compound's ability to increase extracellular neurotransmitter concentrations is quantified, providing a functional measure of its reuptake inhibition activity.
|
| Animal Protocol |
In vivo animal experiments for Zylofuramine are conducted in rodent models to assess its psychostimulant effects. A typical protocol involves administration of the compound via intraperitoneal or oral routes, followed by assessment of locomotor activity, behavioral responses, and neurotransmitter levels in the brain using microdialysis.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Zylofuramine have not been systematically characterized. The compound has a molecular weight of 219.32, molecular formula C14H21NO, and a purity of 99%. It appears as a white to off-white solid powder. Further PK studies are needed to determine its absorption, distribution, metabolism, and excretion profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for Zylofuramine are not extensively reported in the available literature. As a research-use compound, its safety profile has not been formally evaluated in comprehensive preclinical toxicology studies. The compound is intended for research purposes only and is not approved for human therapeutic use. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Zylofuramine is a psychomotor stimulant belonging to the class of amphetamine derivatives. It is also known as D-threo-α-Benzyl-N-ethyltetrahydrofurfurylamine. The compound blocks the reuptake of dopamine, norepinephrine, and serotonin, resulting in increased alertness and energy. This product is for research use only.
|
| Molecular Formula |
C14H21NO
|
|---|---|
| Molecular Weight |
219.32264
|
| Exact Mass |
219.162
|
| CAS # |
3563-92-6
|
| PubChem CID |
71129
|
| Appearance |
White to off-white solid powder
|
| Density |
1.006g/cm3
|
| Boiling Point |
328.8ºC at 760mmHg
|
| Flash Point |
137.2ºC
|
| Index of Refraction |
1.523
|
| LogP |
2.777
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
16
|
| Complexity |
189
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CCN[C@H](CC1=CC=CC=C1)[C@H]2CCCO2
|
| InChi Key |
DOFCLOLKFGSRTG-ZIAGYGMSSA-N
|
| InChi Code |
InChI=1S/C14H21NO/c1-2-15-13(14-9-6-10-16-14)11-12-7-4-3-5-8-12/h3-5,7-8,13-15H,2,6,9-11H2,1H3/t13-,14-/m1/s1
|
| Chemical Name |
(1R)-N-ethyl-1-[(2R)-oxolan-2-yl]-2-phenylethanamine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~455.95 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.40 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (11.40 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (11.40 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.5595 mL | 22.7977 mL | 45.5955 mL | |
| 5 mM | 0.9119 mL | 4.5595 mL | 9.1191 mL | |
| 10 mM | 0.4560 mL | 2.2798 mL | 4.5595 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
